Literature DB >> 17675611

Assessment of metastatic breast cancer response to chemoembolization with contrast agent enhanced and diffusion-weighted MR imaging.

Manon Buijs1, Ihab R Kamel, Josephina A Vossen, Christos S Georgiades, Kelvin Hong, Jean-Francois H Geschwind.   

Abstract

PURPOSE: To assess the value of functional magnetic resonance (MR) imaging in the evaluation of early tumor response after transarterial chemoembolization (TACE) for metastatic breast cancer and to compare tumor response based on functional MR imaging versus traditional assessment based on iodized oil deposition, tumor size, and tumor enhancement.
MATERIALS AND METHODS: For 14 patients with metastatic breast cancer, MR imaging studies before and after TACE were evaluated. Diffusion and contrast medium-enhanced MR imaging was performed on a 1.5-T unit. Parameters evaluated included change in tumor size, enhancement, and apparent diffusion coefficient (ADC) values. Median survival was also calculated in the entire cohort.
RESULTS: A total number of 27 lesions were evaluated, with a mean diameter of 5.5 cm. Although mean tumor size decreased by 18% after treatment, no tumors met the Response Evaluation Criteria In Solid Tumors (RECIST) for complete response (ie, complete disappearance of target lesions) and only seven of 27 met RECIST for partial response (ie, >30% decrease in target lesion size). After treatment, decrease of tumor enhancement in the arterial (32%) and portal venous (39%) phases was statistically significant (P < .0001). Mean tumor ADC increased by 27% (P < .0001) after TACE, whereas ADC remained unchanged in nontumorous liver, spleen, and kidney. Median survival was 25 months for the entire cohort.
CONCLUSION: In patients with breast cancer and liver metastases who were treated with TACE, although changes in tumor size were small, significant early changes in the treated lesions occurred on contrast medium-enhanced and functional MR imaging. These include decrease in tumor enhancement and increase in tumor ADC value, which suggest increasing tumor necrosis and cell death.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17675611     DOI: 10.1016/j.jvir.2007.04.025

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  17 in total

Review 1.  Chemoembolization and radioembolization for metastatic disease to the liver: available data and future studies.

Authors:  Khairuddin Memon; Robert J Lewandowski; Ahsun Riaz; Riad Salem
Journal:  Curr Treat Options Oncol       Date:  2012-09

2.  Yttrium-90 radioembolization stops progression of targeted breast cancer liver metastases after failed chemotherapy.

Authors:  Andrew C Gordon; William J Gradishar; Virginia G Kaklamani; Avesh J Thuluvath; Robert K Ryu; Kent T Sato; Vanessa L Gates; Riad Salem; Robert J Lewandowski
Journal:  J Vasc Interv Radiol       Date:  2014-08-22       Impact factor: 3.464

3.  Diffusion-weighted and Gd-EOB-DTPA-contrast-enhanced magnetic resonance imaging for characterization of tumor necrosis in an animal model.

Authors:  Josephina A Vossen; Manon Buijs; Jean-Francois H Geschwind; Eleni Liapi; Veronica Prieto Ventura; Kwang Hun Lee; David A Bluemke; Ihab R Kamel
Journal:  J Comput Assist Tomogr       Date:  2009 Jul-Aug       Impact factor: 1.826

4.  DW-MRI as a Predictive Biomarker of Radiosensitization of GBM through Targeted Inhibition of Checkpoint Kinases.

Authors:  Terence M Williams; Stefanie Galbán; Fei Li; Kevin A Heist; Craig J Galbán; Theodore S Lawrence; Eric C Holland; Tami L Thomae; Thomas L Chenevert; Alnawaz Rehemtulla; Brian D Ross
Journal:  Transl Oncol       Date:  2013-04-01       Impact factor: 4.243

Review 5.  Improvement of survival and prospect of cure in patients with metastatic breast cancer.

Authors:  Yee Chung Cheng; Naoto T Ueno
Journal:  Breast Cancer       Date:  2011-05-13       Impact factor: 4.239

6.  Breast imaging: A survey.

Authors:  Subbhuraam Vinitha Sree; Eddie Yin-Kwee Ng; Rajendra U Acharya; Oliver Faust
Journal:  World J Clin Oncol       Date:  2011-04-10

Review 7.  Transcatheter intraarterial therapies: rationale and overview.

Authors:  Robert J Lewandowski; Jean-Francois Geschwind; Eleni Liapi; Riad Salem
Journal:  Radiology       Date:  2011-06       Impact factor: 11.105

8.  Transcatheter arterial chemoembolization for hepatic recurrence after curative resection of pancreatic adenocarcinoma.

Authors:  Jin Hyoung Kim; Eugene K Choi; Hyun-Ki Yoon; Gi-Young Ko; Kyu-Bo Sung; Dong Il Gwon
Journal:  Gut Liver       Date:  2010-09-24       Impact factor: 4.519

9.  Short-term effectiveness of radiochemoembolization for selected hepatic metastases with a combination protocol.

Authors:  Shahram Akhlaghpoor; Alireza Aziz-Ahari; Mahasti Amoui; Shahnaz Tolooee; Hossein Poorbeigi; Shahab Sheybani
Journal:  World J Gastroenterol       Date:  2012-10-07       Impact factor: 5.742

Review 10.  Diffusion MRI in early cancer therapeutic response assessment.

Authors:  C J Galbán; B A Hoff; T L Chenevert; B D Ross
Journal:  NMR Biomed       Date:  2016-01-15       Impact factor: 4.044

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.